5 stories mentioning HKG:2268Updated 3h ago
Every FINWIRES story that references HKG:2268, newest first.
WuXi XDC Cayman's (HKG:2268) reported 1.03 billion yuan in adjusted profit attributable to owners for the first half, compared with 747.5 million yuan a year ago, a Monday bourse filing showed.Adjusted EPS moved to 0.75 yuan from 0.57 yuan year over year.For the six months ended June 30, revenue was 3.7 billion yuan, versus 2.7 billion yuan previously, the antibody-drug conjugates company said.
WuXi XDC Cayman (HKG:2268) has an average rating of buy and mean price target of HK$82.03, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
WuXi XDC Cayman (HKG:2268) has an average rating of buy and mean price target of HK$82.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
WuXi XDC Cayman's (HKG:2268) trustee bought back 5.7 million shares of the firm from the market for about HK$57.3 apiece, according to a Friday filing with the Hong Kong bourse.The shares represent 0.45% of the contract research, development and manufacturing organization's issued share capital.
WuXi XDC Cayman (HKG:2268) disclosed plans to buy back $100 million worth of shares, according to a Monday filing with the Hong Kong bourse.The contract research, development and manufacturing organization's shares gained nearly 6% in morning trade Tuesday.The company said its current share price does not reflect its intrinsic value, representing a good opportunity to conduct the buyback.
